No significant correlations were detected between the density of CD169+ cells or the CD169+/CD68+ macrophage ratio and clinical prognoses such as relapse-free survival (RFS), distant relapse-free survival (DRFS), or breast cancer-specific survival (BCSS) (Fig 2D, Tables 2–4). Here, CD68 is linked to breast carcinoma.